Arrowhead Research Corporation Completes Enrollment Of First Cohort In Phase 2a Trial Of Chronic Hepatitis B Candidate ARC-520

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter.

Help employers find you! Check out all the jobs and post your resume.